Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465736 | 0.90 | KMT2A (0.49) | KMT2ACASP3EPHX2CA1CA2 | |
| SCHEMBL6660248 | 0.83 | KMT2A (0.55) | KMT2ACASP3EPHX2FABP5MDM4 | |
| SCHEMBL22000771 | 0.78 | KMT2A (0.48) | KMT2ACASP3EPHX2FABP5MDM4 | |
| SCHEMBL2632350 | 0.77 | KMT2A (0.62) | KMT2ACASP3EPHX2CA1CA2 | |
| SCHEMBL22732440 | 0.77 | KMT2A (0.47) | KMT2ACASP3EPHX2FABP5MDM4 | |
| SCHEMBL6673820 | 0.76 | KMT2A (0.64) | KMT2ACASP3EPHX2CA1CA2 | |
| SCHEMBL13613350 | 0.76 | KMT2A (0.72) | KMT2ACASP3EPHX2CA1CA2 | |
| SCHEMBL13189293 | 0.75 | KMT2A (0.48) | KMT2ACASP3EPHX2CA1CA2 | |
| SCHEMBL20825767 | 0.74 | KMT2A (0.54) | KMT2ACASP3EPHX2FABP5MDM4 | |
| SCHEMBL4344046 | 0.74 | KMT2A (0.54) | KMT2ACASP3EPHX2FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3066085-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2016-09-14 | — | — | EP | claimed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | claimed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | claimed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | claimed |
| US-11021495-B2 | Compositions and methods for inhibiting arginase activity | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200339607-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10597411-B2 | Compositions and methods for inhibiting arginase activity | CALITHERA BIOSCIENCES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | IDO1, INMT, IDO2 | KMT2A 181/4885CASP3 2532/4885EPHX2 868/4885 |
| US-20200339607-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | ARG1, ARG2, PRMT3 | KMT2A 2206/4885CASP3 1342/4885EPHX2 1722/4885 |
| US-10597411-B2 | Compositions and methods for inhibiting arginase activity | ARG1, ARG2, PRMT3 | KMT2A 2206/4885CASP3 1342/4885EPHX2 1722/4885 |
| US-11021495-B2 | Compositions and methods for inhibiting arginase activity | ARG1, ARG2, PRMT3 | KMT2A 2206/4885CASP3 1342/4885EPHX2 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.